An interventional study of vitamin D twice daily and Vitamin D3 oil three times in a year in Optimal Vitamin D Administration, sponsored by University of Helsinki. Completed at 1 site in Finland. Open to female participants aged 70 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-01-08.
Sponsored by University of Helsinki · Not applicable, Interventional, and Treatment
The aim of this study is to compare oral vitamin D supplementation administered in two different ways, namely either twice a day (800IU/d, 292000IU/y) or three times a year (97333IU every 4 months, 292000IU/y) in elderly women in combination with daily supplementation of calcium 1 gram. We will 1)compare the blood concentrations of 25 OH vitamin D in the two treatment groups amd monitor if a sufficient and safe concentration of 25OH D in blood can be maintained with these two treatments.2) Find out seasonal variation in vitamin D concentrations in these treatments. 3) Find out safety of these treatments
University of Helsinki is the lead sponsor of 129 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: vitamin D twice daily
Dietary Supplement: Vitamin D3 oil three times in a year
Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
Blood 25 OH D vitamin concentrations
Time frame: 8 times during the year
serum calcium, 24-hour calcium excretion in urine, creatinine clearance
Time frame: 8 times during the year
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Helsinki